Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG
- None.
- None.
Presentation details:
- Presentation title: Elevating Dermatological Drug Development Through Advanced Inflammatory Marker Targeting Methodology
- Time: Wednesday, April 17th at 11:00 CET
- Location: Hotel Palace
Berlin, Germany
Panel discussion details:
- Presentation title: Route of Administration & Formulations: How Can We Improve?
- Time: Wednesday, April 17th at 14:45 CET
- Location: Hotel Palace
Berlin, Germany
Scinai's Anti-IL-17A/F NanoAbs are designed to address large unmet therapeutic needs of mild to moderate plaque psoriasis patients. As previously reported, these NanoAbs showed the downregulation of psoriasis molecular markers in psoriatic human skin tested in an Ex-vivo study. Scinai is testing its anti-IL-17A/F nanoAb in a Proof of Concept in-vivo study in mice xenografted with human skin induced to express plaque psoriasis. The study is conducted by Prof. Amos Gilhar the head of the internationally renowned Skin Research Laboratory of the Israeli Technion Research Institute. Results of this study are expected in May.
In their talk, Ben-Yedidia and Schön will share information including:
- The unmet need in the mild to moderate plaque psoriasis space
- The clinical potential of a local therapy based on anti-IL-17A/F NanoAbs
- Results from ex-vivo 3D biologic human skin models suggesting the therapeutic potential of Scinai's anti-IL-17A/F NanoAb
- Use of a human xenograft model to evaluate anti-IL-17 NanoAbs as a local treatment for plaque psoriasis
The Dermatology Drug Development summit attracts key opinion leaders and innovators in the dermatology field and bills itself as a "pivotal platform aligning with rapid advancements and emerging needs across inflammatory skin disease treatments".
About Prof. Dr. Michael Schön
Michael Schön is Professor and Director of the Department of Dermatology, Venereology and Allergology at the University Medical Center Göttingen. He is also Vice Dean and Deputy Director for Research and Teaching. In addition, he is the founding director of the Lower Saxony Institute of Occupational Dermatology. Michael has received several awards for his scientific work on immune reactions in inflammation. From 2011 to 2024 he served as Editor-in-Chief of the Journal of the German Dermatological Society. He is currently Secretary General of the European Dermatology Forum (EDF).
About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and pre-clinical and clinical trial design and execution services to early stage biotech companies. Company website: www.scinai.com.
Company Contacts
Investor Relations | +972 8 930 2529 | ir@scinai.com
Business Development | +972 8 930 2529 | bd@scinai.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. Examples of such statements include, but are not limited to, the potential of Scinai's NanoAb program. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to, the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not maintain its listing on Nasdaq; the risk that Scinai will not be successful in expanding its CDMO business or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; the risk that the European Investment Bank (EIB) may accelerate the financial facility under its finance contract with Scinai; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in
Logo: https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg
View original content:SOURCE Scinai Immunotherapeutics Ltd.
FAQ
What event will Dr. Tamar Ben-Yedidia and Prof. Michael Schön present at?
What is the focus of Scinai's presentation at the summit?
What are Scinai's Anti-IL-17A/F NanoAbs designed for?
Who is conducting the Proof of Concept in-vivo study for Scinai's NanoAbs?
When are the results of the in-vivo study expected?
